.Attributes Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after a mean follow-up of 11 months, patients along with metastatic stomach growths who obtained biomarker-matched treatments based upon flowing tumor DNA profiling showed a greater scientific advantage than those receiving unparalleled therapy.